Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer

Brady, Lauren; Carlsson, Jessica; Baird, Anne‐Marie; Casey, Órla; Vlajnic, Tatjana; Murchan, P. M.; Cormican, David; Costigan, Danielle; Gray, Steven G.; Sheils, Orla; O’Neill, Amanda; Watson, R. W. G.; Andrén, Ove; Finn, Stephen

doi:10.1016/j.ctarc.2021.100451

Cited by 6 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 9 Moreover, a very recent report also found that negative ERG expression measured by immunohistochemistry was associated with biochemical progression after RP. 27 Our findings may indicate that measurement of ERG expression could also be used as a predictor of disease progression in patients treated with RP, including admixed populations such as are Hispanic/Latino population.…”

Section: Discussionmentioning

confidence: 75%

Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 75%

Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Immediate progression after prostatectomy was more frequently observed in patients without ERG expression, while loss of PTEN expression was also correlated with rapid disease progression but not in statistically significant manner. Although the combination of negative expression of ERG and PTEN tended to be associated with immediate disease progression, this trend was not statistically significant (34). Shah et al reported heterogeneity regarding ERG and PTEN expression on core needle biopsies from patients with prostate cancer.…”

Section: Relationship Between Erg Expression and Pten Lossmentioning

confidence: 99%

Association Between ERG/PTEN Genes and Pathologic Parameters of Prostate Cancer With an Emphasis on Gleason Score: A Literature Review

SPINOS¹,

GEORGIOU²,

VOULGARI³

et al. 2023

CDP

View full text Add to dashboard Cite

Background/Aim: The purpose of this article was to review the association between the ETS-related gene (ERG) and the phosphatase and tensin homolog (PTEN) genes with pathologic parameters of prostate cancer, emphasizing on Gleason score. Materials and Methods: We performed a PubMed-based search of the literature emphasizing on articles that use pathological techniques, and especially on those that report the use immunohistochemical staining and FISH to investigate the association between ERG and PTEN mutations with the histopathologic parameters of prostate cancer. Results: ERG expression is frequently marked in patients with prostate cancer, usually due to the occurrence of the TMPRSS2:ERG gene fusion. Although some studies reported a potential link between the expression of ERG and Gleason score, there is no strong evidence supporting this finding. On the contrary, there is more solid evidence correlating loss of PTEN expression with worse prognosis and higher Gleason scores. Few studies correlate the over-expression of ERG gene with the loss of PTEN expression. Finally, PTEN and ERG have been studied as potential therapeutic targets, and several promising results have been reported. Conclusion: Although, at some degree, ERG expression seems to be associated with the morphological features of prostate cancer, different studies reported controversial results. However, expression of PTEN is more clearly associated with the pathology and clinical course of the disease. More research is required to elucidate the role of these molecules in the molecular pathology of prostate cancer, as well as their potential use as therapeutic targets.

show abstract

“…Although not ready for clinical use, several emerging biomarkers are being evaluated outside of the commercially available genomic tests. Brady et al 94 demonstrated decrease/loss of erythroblast transformation‐specific‐related gene expression levels are associated with immediate biochemical progression following radical prostatectomy with decrease/loss of phosphatase and TENsin homolog deleted on chromosome 10 expression demonstrating a trend toward immediate biochemical progression. Circulating tumor DNA (ctDNA) is also being evaluated in predicting rapid progression after prostatectomy though data are conflicting.…”

Section: Localized Pcamentioning

confidence: 99%

Genomic biomarkers to guide precision radiotherapy in prostate cancer

et al. 2022

View full text Add to dashboard Cite

Our ability to prognosticate the clinical course of patients with cancer has historically been limited to clinical, histopathological, and radiographic features. It has long been clear however, that these data alone do not adequately capture the heterogeneity and breadth of disease trajectories experienced by patients. The advent of efficient genomic sequencing has led to a revolution in cancer care as we try to understand and personalize treatment specific to patient clinico-genomic phenotypes. Within prostate cancer, emerging evidence suggests that tumor genomics (e.g., DNA, RNA, and epigenetics) can be utilized to inform clinical decision making. In addition to providing discriminatory information about prognosis, it is likely tumor genomics also hold a key in predicting response to oncologic therapies which could be used to further tailor treatment recommendations. Herein we review select literature surrounding the use of tumor genomics within the management of prostate cancer, specifically leaning toward analyticallyThe Prostate.

show abstract

Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer

Cited by 6 publications

References 33 publications

Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer

Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer

Association Between ERG/PTEN Genes and Pathologic Parameters of Prostate Cancer With an Emphasis on Gleason Score: A Literature Review

Genomic biomarkers to guide precision radiotherapy in prostate cancer

Contact Info

Product

Resources

About